The client previously purchased ISAB’s aerosol generation platform PreciseInhale^®, in November 2020, plus two in vivo exposure modules. PreciseInhale^® and its suite of advanced exposure modules can generate voluminous high-precision data through all phases of preclinical research, from in vitro to in vivo, from even tiny amounts of test substance.

Now the Department is complementing its PreciseInhale^® suite with ISAB’s advanced 3D cell exposure module XposeALI^® for a total order value of 62 000 Euros. Unlike previous cell exposure systems - where cells are immersed in a liquid - XposeALI^® enables the study of the permeability of substances in an Air-Liquid Interface - a more physiological approach that mimics the conditions and processes occurring in the lungs.

ISAB CEO Manoush Masarrat: "We’re very pleased that the expert team at the University of Vienna are now complementing their PreciseInhale^® system with our unique cell exposure module XposeALI^®. This is a purchase that shows clearly the advanced precision and capabilities of our equipment – and how it can grow and keep delivering to research teams and organizations to meet all their inhalation research needs."

To read more about XposeALI^® go here.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and Dissolv It® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on September 16 2022.